Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02628067
Title Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

bile duct carcinoma

lung small cell carcinoma

thyroid gland carcinoma

Advanced Solid Tumor

malignant mesothelioma


salivary gland cancer

endometrial carcinoma

gallbladder adenocarcinoma

neuroendocrine tumor

cervix carcinoma

vulva carcinoma

anal canal carcinoma



Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

No variant requirements are available.